InvestorsObserver
×
News Home

Should You Buy Vascular Biogenics Ltd (VBLT) Stock on Monday?

Monday, October 02, 2023 12:40 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Vascular Biogenics Ltd (VBLT) Stock on Monday?

Vascular Biogenics Ltd (VBLT) stock is higher by 19.05% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Vascular Biogenics Ltd has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VBLT!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With VBLT Stock Today?

Vascular Biogenics Ltd (VBLT) stock has gained 3.11% while the S&P 500 is lower by -0.48% as of 12:31 PM on Monday, Oct 2. VBLT has gained $0.01 from the previous closing price of $0.24 on volume of 340,446 shares. Over the past year the S&P 500 is higher by 16.01% while VBLT has gained 56.25%. VBLT lost -$0.21 per share in the over the last 12 months.

More About Vascular Biogenics Ltd

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics. Click Here to get the full Stock Report for Vascular Biogenics Ltd stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App